Stay updated on Moderna Press Releases
Sign up to get notified when there's something new on the Moderna Press Releases page.

Latest updates to the Moderna Press Releases page
- Check2 days agoChange DetectedNew press release items and dates were added to the News & Blog Posts section, expanding 2026–2028 coverage; at the same time, the header stock price and volume values were removed.SummaryDifference8%

- Check9 days agoChange DetectedThe page now reflects the latest stock data and adds two significant press releases (FDA approval for mFLUSIVA and a Phase 1 trial initiation), while older stock figures and a prior press release were removed.SummaryDifference5%

- Check16 days agoChange DetectedThe page now shows updated stock data and adds a new press release entry for Moderna's Q2 2026 results dated July 31, 2026, while removing the previous stock figures and an earlier press release from June 1, 2026.SummaryDifference1%

- Check23 days agoChange DetectedModerna's stock quote and trading volume on the page were updated from $61.82 and 4.55M to $54.07 and 4.43M, respectively.SummaryDifference0.5%

- Check31 days agoChange DetectedThe page adds an updated stock quote ($61.82) and trading volume (4.55M) and includes a new press release headline dated July 16, 2026 announcing the first participant dosed in a Phase 1 trial evaluating an investigational tumor-targeted cancer antigen therapy in solid tumors.SummaryDifference1%

- Check38 days agoChange DetectedAdded: Q2 2026 financial results announcement, appointment of Michael McDonnell to Moderna's Board of Directors, and updated stock data (price 68.27, volume 9.18M) with dates July 9 and 8, 2026. Removed: the prior stock price (79.76) and two May 2026 press releases (TIME recognition and NEJM publication).SummaryDifference5%

Stay in the know with updates to Moderna Press Releases
Enter your email address, and we'll notify you when there's something new on the Moderna Press Releases page.